Cargando…

A nomogram for predicting the HER2 status in female patients with breast cancer in China: a nationwide, multicenter, 10-year epidemiological study

BACKGROUND: The concordance rate of human epidermal growth factor receptor 2 (HER2) status between core needle biopsy (CNB) and subsequent excisional biopsies of the same tumor varies from 81 to 96%, which may cause inappropriate neoadjuvant therapy that impair the potential benefit from HER2 target...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Huimin, Xie, Peiling, Li, Zhuoying, Huang, Rong, Feng, Weiliang, Kong, Yanan, Xu, Feng, Zhao, Lin, Song, Qingkun, Li, Jing, Zhang, Baoning, Fan, Jinhu, Qiao, Youlin, Xie, Xiaoming, Zheng, Shan, He, Jianjun, Wang, Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500005/
https://www.ncbi.nlm.nih.gov/pubmed/31054583
http://dx.doi.org/10.1186/s13000-019-0806-4
_version_ 1783415869668327424
author Zhang, Huimin
Xie, Peiling
Li, Zhuoying
Huang, Rong
Feng, Weiliang
Kong, Yanan
Xu, Feng
Zhao, Lin
Song, Qingkun
Li, Jing
Zhang, Baoning
Fan, Jinhu
Qiao, Youlin
Xie, Xiaoming
Zheng, Shan
He, Jianjun
Wang, Ke
author_facet Zhang, Huimin
Xie, Peiling
Li, Zhuoying
Huang, Rong
Feng, Weiliang
Kong, Yanan
Xu, Feng
Zhao, Lin
Song, Qingkun
Li, Jing
Zhang, Baoning
Fan, Jinhu
Qiao, Youlin
Xie, Xiaoming
Zheng, Shan
He, Jianjun
Wang, Ke
author_sort Zhang, Huimin
collection PubMed
description BACKGROUND: The concordance rate of human epidermal growth factor receptor 2 (HER2) status between core needle biopsy (CNB) and subsequent excisional biopsies of the same tumor varies from 81 to 96%, which may cause inappropriate neoadjuvant therapy that impair the potential benefit from HER2 targeted therapy for patients. This study aimed to establish a nomogram to predict the HER2 status pre-operatively as an auxiliary diagnosis to CNB assessment. METHODS: Among 4211 breast cancer patients cataloged in the Nation-wide Multicenter 10-year Retrospective Clinical Epidemiological Study of Breast Cancer in China, 2291 patients with complete relevant information were included in this study, which were further randomized 3:1 and divided into a training set and a validation set. The nomogram was established based on independent predictors of HER2 positivity recognized by logistic regression analysis and further validated internally and externally. RESULTS: The multivariate logistic regression analysis showed that T-stage, N-stage, estrogen receptor (ER) status, progesterone receptor (PR) status were independent predictors for HER2 status. The nomogram was thereby constructed by those independent predictors as well as histology type. The areas under the receiver operating characteristic curve (AUC) of the training set and the validation set were 0.636 and 0.681, respectively. The calibration plots demonstrated good fitness of the nomogram for HER2 status prediction. With the optimal cutoff value, the nomogram yielded 80.0% sensitivity, 43.1% specificity in the training set and 81.1% sensitivity, 49.8% specificity in the validation set. CONCLUSIONS: The present nomogram can provide valuable information on HER2 status and combined with standard CNB assessment, clinicians could make more appropriate decision on neoadjuvant therapy of breast cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13000-019-0806-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6500005
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65000052019-05-09 A nomogram for predicting the HER2 status in female patients with breast cancer in China: a nationwide, multicenter, 10-year epidemiological study Zhang, Huimin Xie, Peiling Li, Zhuoying Huang, Rong Feng, Weiliang Kong, Yanan Xu, Feng Zhao, Lin Song, Qingkun Li, Jing Zhang, Baoning Fan, Jinhu Qiao, Youlin Xie, Xiaoming Zheng, Shan He, Jianjun Wang, Ke Diagn Pathol Research BACKGROUND: The concordance rate of human epidermal growth factor receptor 2 (HER2) status between core needle biopsy (CNB) and subsequent excisional biopsies of the same tumor varies from 81 to 96%, which may cause inappropriate neoadjuvant therapy that impair the potential benefit from HER2 targeted therapy for patients. This study aimed to establish a nomogram to predict the HER2 status pre-operatively as an auxiliary diagnosis to CNB assessment. METHODS: Among 4211 breast cancer patients cataloged in the Nation-wide Multicenter 10-year Retrospective Clinical Epidemiological Study of Breast Cancer in China, 2291 patients with complete relevant information were included in this study, which were further randomized 3:1 and divided into a training set and a validation set. The nomogram was established based on independent predictors of HER2 positivity recognized by logistic regression analysis and further validated internally and externally. RESULTS: The multivariate logistic regression analysis showed that T-stage, N-stage, estrogen receptor (ER) status, progesterone receptor (PR) status were independent predictors for HER2 status. The nomogram was thereby constructed by those independent predictors as well as histology type. The areas under the receiver operating characteristic curve (AUC) of the training set and the validation set were 0.636 and 0.681, respectively. The calibration plots demonstrated good fitness of the nomogram for HER2 status prediction. With the optimal cutoff value, the nomogram yielded 80.0% sensitivity, 43.1% specificity in the training set and 81.1% sensitivity, 49.8% specificity in the validation set. CONCLUSIONS: The present nomogram can provide valuable information on HER2 status and combined with standard CNB assessment, clinicians could make more appropriate decision on neoadjuvant therapy of breast cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13000-019-0806-4) contains supplementary material, which is available to authorized users. BioMed Central 2019-05-04 /pmc/articles/PMC6500005/ /pubmed/31054583 http://dx.doi.org/10.1186/s13000-019-0806-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Zhang, Huimin
Xie, Peiling
Li, Zhuoying
Huang, Rong
Feng, Weiliang
Kong, Yanan
Xu, Feng
Zhao, Lin
Song, Qingkun
Li, Jing
Zhang, Baoning
Fan, Jinhu
Qiao, Youlin
Xie, Xiaoming
Zheng, Shan
He, Jianjun
Wang, Ke
A nomogram for predicting the HER2 status in female patients with breast cancer in China: a nationwide, multicenter, 10-year epidemiological study
title A nomogram for predicting the HER2 status in female patients with breast cancer in China: a nationwide, multicenter, 10-year epidemiological study
title_full A nomogram for predicting the HER2 status in female patients with breast cancer in China: a nationwide, multicenter, 10-year epidemiological study
title_fullStr A nomogram for predicting the HER2 status in female patients with breast cancer in China: a nationwide, multicenter, 10-year epidemiological study
title_full_unstemmed A nomogram for predicting the HER2 status in female patients with breast cancer in China: a nationwide, multicenter, 10-year epidemiological study
title_short A nomogram for predicting the HER2 status in female patients with breast cancer in China: a nationwide, multicenter, 10-year epidemiological study
title_sort nomogram for predicting the her2 status in female patients with breast cancer in china: a nationwide, multicenter, 10-year epidemiological study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500005/
https://www.ncbi.nlm.nih.gov/pubmed/31054583
http://dx.doi.org/10.1186/s13000-019-0806-4
work_keys_str_mv AT zhanghuimin anomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT xiepeiling anomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT lizhuoying anomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT huangrong anomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT fengweiliang anomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT kongyanan anomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT xufeng anomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT zhaolin anomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT songqingkun anomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT lijing anomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT zhangbaoning anomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT fanjinhu anomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT qiaoyoulin anomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT xiexiaoming anomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT zhengshan anomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT hejianjun anomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT wangke anomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT zhanghuimin nomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT xiepeiling nomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT lizhuoying nomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT huangrong nomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT fengweiliang nomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT kongyanan nomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT xufeng nomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT zhaolin nomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT songqingkun nomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT lijing nomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT zhangbaoning nomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT fanjinhu nomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT qiaoyoulin nomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT xiexiaoming nomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT zhengshan nomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT hejianjun nomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy
AT wangke nomogramforpredictingtheher2statusinfemalepatientswithbreastcancerinchinaanationwidemulticenter10yearepidemiologicalstudy